Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MOMA 313 (Primary) ; Olaparib
  • Indications Advanced breast cancer; Male breast cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MOMA Therapeutics

    • Most Recent Events

    • 17 Apr 2025 According to a MOMA Therapeutics media release, abstracts containing trial design of this trial is currently available on the AACR website. The posters can be accessed through the News & Publications tab on the MOMA Therapeutics website at the time of each presentations starting session.
    • 17 Apr 2025 According to a MOMA Therapeutics media release, trial design of this trial will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
    • 08 Jan 2025 According to a MOMA Therapeutics media release, initial readout of olaparib combination efficacy data is anticipated in mid-2026, with development of the proprietary combination with MOMA-989 to initiate in late 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top